Affinity Investment Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Affinity Investment Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,215	Closed	-$787K	–	212
2023 Q1	$787K	Sell	7,215 -38	-0.5%	-$4.2K	0.42%	91
2022 Q4	$825K	Buy	7,253 +75	+1%	+$6.23K	0.38%	94
2022 Q3	$444K	Hold	7,178	–	–	0.23%	141
2022 Q2	$573K	Sell	7,178 -278	-4%	-$26.3K	0.28%	122
2022 Q1	$784K	Sell	7,456 -1,779	-19%	-$173K	0.32%	115
2021 Q4	$995K	Sell	9,235 -1,183	-11%	-$129K	0.4%	89
2021 Q3	$1.14M	Sell	10,418 -1,361	-12%	-$141K	0.51%	61
2021 Q2	$1.1M	Hold	11,779	–	–	0.5%	67
2021 Q1	$1.08M	Sell	11,779 -548	-4%	-$46.2K	0.4%	75
2020 Q4	$902K	Sell	12,327 -4,477	-27%	-$333K	0.36%	77
2020 Q3	$1.3M	Sell	16,804 -7,121	-30%	-$490K	0.57%	53
2020 Q2	$1.33M	Sell	23,925 -4,489	-16%	-$192K	0.63%	53
2020 Q1	$842K	Buy	28,414 +6,660	+31%	+$225K	0.43%	54
2019 Q4	$787K	Hold	21,754	–	–	0.29%	64
2019 Q3	$592K	Sell	21,754 -2,605	-11%	-$67.4K	0.19%	66
2019 Q2	$586K	Sell	24,359 -2,393	-9%	-$60.7K	0.17%	73
2019 Q1	$707K	Sell	26,752 -1,432	-5%	-$33.9K	0.14%	68
2018 Q4	$551K	Sell	28,184 -3,524	-11%	-$69.1K	0.1%	73
2018 Q3	$621K	Buy	+31,708	New	+$603K	0.08%	76

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Affinity Investment Advisors's HZNP Position: Q2 2023 in Review

Affinity Investment Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 7,215 shares — an estimated $787K sold.

Affinity Investment Advisors first reported a position in HZNP in Q3 2018 and held it in 19 quarters. The position peaked at $1.33M in Q2 2020. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Affinity Investment Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Affinity Investment Advisors sold 7,215 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $787K.
Affinity Investment Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2018 and held it in 19 quarters.
Affinity Investment Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.33M in Q2 2020.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Affinity Investment Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.